Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-ana...
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
About this item
Full title
Author / Creator
Publisher
United States: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: Public Library of Science
Subjects
More information
Scope and Contents
Contents
Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia. Ibrutinib has an increased risk of atrial fibrillation but the mechanism is unknown, and hypertension may play a role in the pathogenesis of thi...
Alternative Titles
Full title
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_2185065767
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2185065767
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0211228
